According to Novo Nordisk, the facility, which will more than double the site's footprint, will be designed as a multi-product facility to accommodate current and future processes.

“Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases,” said Henrik Wulff, Novo Nordisk’s executive vice president, Product Supply, Quality & IT.

The construction projects, Novo Nordisk said, are already underway and will be completed in stages between 2026 and 2028. The investment is expected to create more than 500 new jobs.